These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18794729)

  • 1. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
    Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
    Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
    Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
    Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
    He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
    Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of
    Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
    Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
    Kivistö KT; Niemi M
    Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
    Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
    Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.